TTD | Drug: D05RJP

Drug General Information
Drug ID	D05RJP
Former ID	DCL000903
Drug Name	Oblimersen
Indication	Advanced melanoma; Multiple myeloma [ICD9: 172, 203.0; ICD10:C43, C90]		Phase 3	[521495], [543024]
Company	Genta Incorp
Formula	C172H221N62O91P17S17
CAS Number	CAS 190977-41-4
PubChem Compound ID	71587613
SuperDrug ATC ID	L01XX36
Target and Pathway
Target(s)	Apoptosis regulator Bcl-2	Target Info	Inhibitor	[537114]
KEGG Pathway	NF-kappa B signaling pathway
	HIF-1 signaling pathway
	Sphingolipid signaling pathway
	Protein processing in endoplasmic reticulum
	PI3K-Akt signaling pathway
	Apoptosis
	Adrenergic signaling in cardiomyocytes
	Focal adhesion
	Neurotrophin signaling pathway
	Cholinergic synapse
	Amyotrophic lateral sclerosis (ALS)
	Toxoplasmosis
	Tuberculosis
	Hepatitis B
	Epstein-Barr virus infection
	Pathways in cancer
	MicroRNAs in cancer
	Colorectal cancer
	Prostate cancer
	Small cell lung cancer
NetPath Pathway	IL5 Signaling Pathway
	TCR Signaling Pathway
	IL2 Signaling Pathway
	IL3 Signaling Pathway
	Leptin Signaling Pathway
	RANKL Signaling Pathway
	TSLP Signaling Pathway
PANTHER Pathway	Apoptosis signaling pathway
	Oxidative stress response
	CCKR signaling map ST
Pathway Interaction Database	Role of Calcineurin-dependent NFAT signaling in lymphocytes
	IL2-mediated signaling events
	IL2 signaling events mediated by PI3K
	Ceramide signaling pathway
	Direct p53 effectors
	RXR and RAR heterodimerization with other nuclear receptor
	ATF-2 transcription factor network
	C-MYB transcription factor network
	HIV-1 Nef: Negative effector of Fas and TNF-alpha
	Caspase Cascade in Apoptosis
	Signaling events mediated by Stem cell factor receptor (c-Kit)
	EPO signaling pathway
	IL2 signaling events mediated by STAT5
	Validated targets of C-MYC transcriptional repression
Reactome	Activation of BAD and translocation to mitochondria
	BH3-only proteins associate with and inactivate anti-apoptotic BCL-2 members
	The NLRP1 inflammasome
WikiPathways	DNA Damage Response (only ATM dependent)
	Senescence and Autophagy in Cancer
	IL-2 Signaling Pathway
	FAS pathway and Stress induction of HSP regulation
	Focal Adhesion
	Kit receptor signaling pathway
	IL-3 Signaling Pathway
	Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways
	Apoptosis
	Nanoparticle triggered autophagic cell death
	Amyotrophic lateral sclerosis (ALS)
	Integrated Pancreatic Cancer Pathway
	Corticotropin-releasing hormone
	Interleukin-11 Signaling Pathway
	Prostate Cancer
	miR-targeted genes in muscle cell - TarBase
	miR-targeted genes in lymphocytes - TarBase
	miR-targeted genes in leukocytes - TarBase
	Integrated Breast Cancer Pathway
	Integrated Cancer pathway
	Intrinsic Pathway for Apoptosis
	Apoptosis Modulation and Signaling
	TP53 Network
	Influenza A virus infection
	IL-5 Signaling Pathway
References
Ref 521495	ClinicalTrials.gov (NCT00024440) Fludarabine and Cyclophosphamide With or Without Oblimersen in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia. U.S. National Institutes ofHealth.
Ref 543024	(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8269).
Ref 537114	Emerging therapies for multiple myeloma. Expert Opin Emerg Drugs. 2009 Mar;14(1):99-127.

Drug Information